Basic concepts in opioid prescribing and current concepts of opioid-mediated effects on driving

Ochsner Journal

Volumn 13, Issue 4, 2013, Pages 525-532

  Kaye, Adam M ^a   Kaye, Alan D ^b   Lofton, Elise C ^c  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Analgesics opioid; Chronic pain; Medication therapy management; Opioid related disorders

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS OXYCODONE PLUS OXYCODONE TEREPHTHALATE; ATROPINE PLUS DIPHENOXYLATE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; COCODAMOL; CODEINE; DEXTROPROPOXYPHENE; DICLOFENAC; DICLOFENAC EPOLAMINE; DULOXETINE; FENTANYL; FENTANYL CITRATE; HYDROCODONE; HYDROCODONE BITARTRATE PLUS IBUPROFEN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; IBUDONE; IBUPROFEN; METHADONE; MORPHINE; MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE; NARCOTIC ANALGESIC AGENT; NUMORPHONE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PERCOCET; PETHIDINE; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LIVER FAILURE; ANALGESIA; ANDROGEN DEFICIENCY; BRADYCARDIA; CAR DRIVING; CHRONIC PAIN; CONSTIPATION; CONVULSION; COUGHING; DELUSION; DIARRHEA; DRIVING ABILITY; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EUPHORIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART INJURY; HORMONE DEFICIENCY; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LIVER INJURY; NAUSEA; OPIATE ADDICTION; OPIOID INDUCED ANDROGEN DEFICIENCY; OTOTOXICITY; PAIN; PATIENT CONTROLLED ANALGESIA; PERCEPTION DEAFNESS; POSTOPERATIVE PAIN; PRESCRIPTION; PRURITUS; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; TORSADE DES POINTES; TRAFFIC ACCIDENT; UNSPECIFIED SIDE EFFECT;

EID: 84890373318     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. American Academy of Pain Medicine. Get the facts on pain. http://www.painmed.org/patientcenter/facts_on_pain.aspx. Accessed September 20, 2013.
2. Fishman, SM. The clinician's dilemma: under-treated pain versus prescription drug misuse. Responsible Opioid Prescribing: A Clinician's Guide. 2012. http://www.fsmb.org/pdf/opioid-c1.pdf. Accessed September 20, 2013.
3. Fox CJ, Hawney HA, Kaye AD. Opioids: Pharmacokinetics and pharmacodynamics. In: Vadivelu N, Urman RD, Hines RL, eds. Essentials of Pain Management. New York, NY: Springer; 2011: 91-103.
4. US Food and Drug Administration. New safety measures announced for extended-release and long-acting opioids. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm363722.htm. Accessed September 23, 2013.
5. Ahmedzai SH. Personalized medicine-one size fits one: tailoring pain therapy to individuals' needs. J Pain Palliat Care Pharmacother. 2013 Mar;27(1):83-85.
6. Rachinger-Adam B, Conzen P, Azad SC. Pharmacology of peripheral opioid receptors. Curr Opin Anaesthesiol. 2011 Aug; 24(4):408-413.
7. IMS Health. Top 25 medicines by dispensed prescriptions (U.S.) http://www.imshealth.com/cds/imshealth/Global/Content/ Corporate/Press%20Room/2012_U.S/Top_25_Medicines _Dispensed_Prescriptions_U.S.pdf. Accessed September 23, 2013.
8. Kaye AM, Kaye AD. Special concerns regarding commonly prescribed drugs. In: Kaye AD, Urman RD, eds. Understanding Pain: What You Need to Know to Take Control. Santa Barbara, CA: Praeger/ABC-CLIO; 2011:54-61.
9. Singla A, Sloan P. Pharmacokinetic evaluation of hydrocodone/ acetaminophen for pain management. J Opioid Manag. 2013 Jan-Feb;9(1):71-80.
10. Barkin RL, Barkin SJ, Barkin DS. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. Am J Ther. 2006 Nov-Dec;13(6):534-542.
11. Pani PP, Trogu E, Maremmani I, Pacini M. QTc interval screening for cardiac risk in methadone treatment of opioid dependence. Cochrane Database Syst Rev. 2013 Jun 20;6:CD008939.
12. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med. 2009 Mar 17;150(6):387-395. Epub 2009 Jan 19.
13. Melmon KL, Morelli HF, Hoffman BB, Nierenberg DW. Clinical Pharmacology: Basic Principles in Therapeutics. New York, NY: McGraw-Hill; 1992:729.
14. Frampton JE. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs. 2010 Sep 10;70(13):1719-1743.
15. Ho T, Vrabec JT, Burton AW. Hydrocodone use and sensorineural hearing loss. Pain Physician. 2007 May;10(3):467-472.
16. Friedman RA, House JW, Luxford WM, Gherini S, Mills D. Profound hearing loss associated with hydrocodone/ acetaminophen abuse. Am J Otol. 2000 Mar;21(2):188-191.
17. Brown RT, Zueldorff M. Opioid substitution with methadone and buprenorphine: sexual dysfunction as a side effect of therapy. Heroin Addict Relat Clin Probl. 2007; 9(1):35-44.
18. Colameco S, Coren JS. Opioid-induced endocrinopathy. J Am Osteopath Assoc. 2009 Jan;109(1):20-25.
19. Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010 Feb;31(1):98-132. Epub 2009 Nov 10.
20. Azizi F, Vagenakis AG, Longcope C, Ingbar SH, Braverman LE. Decreased serum testosterone concentration in male heroin and methadone addicts. Steroids. 1973 Oct;22(4):467-472.
21. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002 Oct;3(5):377-384.
22. Stanos SP, Bruckenthal P, Barkinc RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc. 2012 Jul;87(7):683-694.
23. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioiddependent/ tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage. 2003 Jun;25(6):559-577.
24. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother. 2002;16(1):9-28.
25. Nilsen HK, Landr NI, Kaasa S, Jenssen GD, Fayers P, Borchgrevink PC. Driving functions in a video simulator in chronic non-malignant pain patients using and not using codeine. Eur J Pain. 2011 Apr;15(4):409-415. Epub 2010 Oct 13.
26. Kaye AD, Gayle J, Kaye AM. Pharmacology principles. In: Urman RD, Kaye AD, eds. Moderate and Deep Sedation in Clinical Practice. New York, NY: Cambridge Press Publishing; 2012:15-32.
27. Wilhelmi BG, Cohen SP. A framework for "driving under the influence of drugs" policy for the opioid using driver. Pain Physician. 2012 Jul;15(3 Suppl):ES215-230.